Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Intelligence Report 2026 — Updated June 2026

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application (Hospital and Clinic, Pharmacy, Other), by Types (Pegfilgrastim, Lenograstim, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 170

Forecast Period: 2026 - 2033

Market Size: $4550 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 170

Forecast Period: 2026 - 2033

Market Size: $4550 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Overview

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) agents—pegylated filgrastim biosimilars and originators—are essential once-per-cycle biologics that prevent chemotherapy-induced neutropenia. With global oncology volumes rebounding post-COVID-19, the Long-acting G-CSF market size is estimated at USD 5.7 billion (2025 base year) and is projected to reach USD 8.9 billion by 2033, translating to a 6.2% CAGR growth outlook. This market forecast is underpinned by the shift toward value-based cancer care, rapid adoption of biosimilars, and payer pressure to curtail hospitalization costs, collectively driving industry expansion across both mature and emerging markets.

Loading chart…

North America commands the largest revenue share (>45%) thanks to favorable reimbursement (average selling price +6% margin) and robust biosimilar uptake, while Asia-Pacific is the fastest-growing region (>9% CAGR) propelled by expanding universal health coverage and accelerated WHO pre-qualification of biosimilars. Key forces reshaping the landscape include: (1) regulatory harmonization—FDA & EMA streamlining extrapolation across indications; (2) competitive intensity—over ten pegfilgrastim biosimilars launched since 2018 compressing prices 25–40%; and (3) supply-chain resilience—manufacturers investing in dual-sourced APIs and on-shore fill-finish to mitigate geopolitical risk. Collectively, these dynamics underpin a cautiously optimistic growth outlook for stakeholders along the long-acting G-CSF value chain.

Report Overview

Report Attribute	Details
Market size value in 2025	4.55 billion
Revenue forecast in 2033	7.36 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen; Mylan; Kashiv BioSciences; Pfizer; Fresenius Kabi; Coherus BioSciences; Sandoz; Italfarmaco SpA; Evive Biotech; Chugai Pharmaceutical; Jiangsu Hengrui Pharmaceuticals; Amoytop Biotech; Qilu Pharmaceutical; CSPC Baike Biopharma; SL Pharm; Lunan Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Chemotherapy cycles are intensifying globally; a single dose of long-acting G-CSF replaces daily injections, aligning with hospital cost-containment mandates and driving >10% YoY volume growth in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market.

Biosimilar pegfilgrastim launches in the U.S. and EU have compressed average selling prices by 25–35%, unlocking payer restrictions and expanding eligible patient pools, directly enlarging the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size beyond prior consensus forecasts.

Restraints

CMS’s 2024 OPPS rule bundles G-CSF into 340B ceiling prices, eroding hospital margins and prompting oncologists to shift patients back to short-acting formulations when DRG budgets tighten, capping the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market growth forecast at mid-single digits in the U.S.

Patent cliffs for originator pegfilgrastim have triggered supply-chain destocking as distributors await further biosimilar entrants, creating a temporary revenue vacuum that masks underlying demand strength.

Opportunities

Emerging markets (LATAM, ASEAN) are adopting national febrile-neutropenia prophylaxis guidelines; local fill-finish partnerships can cut landed costs by 20%, enabling vendors to price at parity with short-acting G-CSF and capture a previously untapped $450 million opportunity within the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size.

Next-generation Fc-fusion and albumin-coated long-acting G-CSF candidates show 40% longer half-life, opening once-per-cycle subcutaneous self-administration in home-care oncology, a segment expected to outpace hospital channels 2:1 through 2028.

Challenges

Manufacturing pegfilgrastim requires high-molecular-weight PEGylation suites; only five CDMOs globally hold FDA validated capacity, creating a 12–18 month queue that delays biosimilar launches and constrains volume upside even as demand accelerates.

Regulators (EMA, PMDA) are tightening immunogenicity thresholds for pegylated biologics, forcing costly post-marketing surveillance studies that can add $30–40 million per sponsor and erode IRR for late entrants targeting the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market.

Market Segmentation

Loading chart…

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) segmentation by application is dominated by chemotherapy-induced neutropenia, which accounts for roughly three-quarters of global revenue. The high cyclical demand generated by myelosuppressive regimens across solid tumours and haematological malignancies creates a predictable replacement market, while clinical guidelines mandate primary prophylaxis when febrile-neutropenia risk exceeds 20 %. Auto-immune diseases such as Felty’s syndrome or SLE-related neutropenia represent a small but rising niche; payers require documented failure of conventional immunosuppressants, limiting volumes yet allowing premium pricing because of chronic dosing. Other applications—including haematopoietic stem-cell mobilisation, severe congenital neutropenias, and aplastic anaemia—collectively contribute <10 % of sales; these orphan-like settings are reimbursed via dedicated pathways, insulating them from oncology tender pressure but capping absolute patient numbers.

Market taxonomy by type distinguishes the originator Pegfilgrastim from its biosimilar counterparts. Pegfilgrastim still captures the largest revenue slice, supported by longitudinal safety data and entrenched trust among oncologists; however, share erodes 3-5 % annually as formularies institute preferential biosimilar policies. Biosimilars—comprising both pegylated and non-pegylated long-acting constructs—have reduced list prices 25-40 %, unlocking demand in Eastern Europe, Latin America, and emerging Asian markets where cost-effectiveness thresholds dominate procurement. The competitive dynamic is intensified by differentiated delivery devices (on-body injectors vs pre-filled syringes) and varying half-lives, forcing suppliers to compete on nursing convenience as well as price. Overall, the type-based Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) segmentation illustrates a classic life-cycle transition: originator defence through real-world evidence and value-added services, biosimilars capturing share via tender-driven switches, and cumulative market expansion as affordable access broadens treatment adherence.

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segmentation Breakdown8 items

Application

Hospital and Clinic

Pharmacy

Other

Types

Pegfilgrastim

Lenograstim

Other

Regional Insights

Loading chart…

North America remains the dominant revenue contributor in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, underpinned by >90% prophylactic adoption of biosimilars, CMS bundled-payment incentives, and a dense network of oncology centers. Europe follows, propelled by tender-driven procurement, mandatory cost-effectiveness reviews, and rapid uptake of PEGylated biosimilars that compress pricing 25–30% below originators.

Asia Pacific is the fastest-expanding region—Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market growth is forecast at a 14% CAGR—fueled by rising chemotherapy volumes in China and India, government-backed oncology infrastructure funds, and accelerating local biosimilar launches. Latin America benefits from universal cancer coverage policies, G-CSF inclusion in essential medicine lists, and FDI by global biologics manufacturers building fill-finish sites, though per-capita penetration still sits at one-third of U.S. levels.

Middle East & Africa is emerging, driven by Saudi and UAE Vision 2030 health-sector investments, compulsory health insurance, and the roll-out of cold-chain 3PL networks. Yet tendering constraints and limited reimbursement cap market penetration to ~5% of oncology patients.

Competitive Landscape

The Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) competitive landscape is moderately consolidated, dominated by a handful of multinational originators and a widening ring of biosimilar entrants with regional clout. Global incumbents leverage established regulatory dossiers and hospital tender relationships, while local players from China and India compete on landed cost and accelerated approval pathways; pricing, differentiated delivery devices, and pharmacoeconomic dossiers are the principal levers, with distribution depth and WHO-prequalification increasingly determining access in lower-income markets.

To sustain relevance, companies pursue staggered patent litigation settlements, capacity-sharing joint ventures, and lifecycle improvements such as novel PEGylation or on-body injectors. Differentiation now hinges on demonstrating comparable immunogenicity with shorter injection training, securing subcutaneous administration outpatients, and offering cold-chain-light presentations. Margin pressure is intensifying as tenders adopt weighted-average price caps and reference-pricing corridors compress across the EU, Japan, and emerging markets, forcing manufacturers to extract cost savings through end-to-end vertical integration and dual-sourcing API to mitigate supply-chain risks.

Companies Strategy Snapshot6 items

Amgen defends originator share via bundled risk-sharing contracts and next-gen auto-injector

Mylan banks on high-volume regional pricing and rapid dossier rollout across LATAM

Kashiv BioSciences targets vertical integration with U.S.-based fill-finish and API expansion

Coherus BioSciences pushes indication-extension trials to widen payer coverage

Sandoz leverages global hospital tenders and prefilled synergy with oncology portfolio

Evive Biotech secures partnerships in MEA for local dossier and cold-chain reduction

Market Ecosystem

The Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) ecosystem spans three tightly linked tiers: upstream biologic API producers supplying PEGylation reagents and CHO-based biosynthesis; midstream innovators conducting glycoengineering, fill-finish, and regulatory CMC packages; downstream hospital tenders, specialty pharmacies, and outpatient oncology clinics administering single-dose pegfilgrastim or biosimilar equivalents. Value accrues first to IP-holders controlling PEG-protein conjugation patents, then to contract manufacturers achieving > 99.5 % monopegylated species yield, and finally to payers capturing reduced febrile-neutropenia hospitalization costs.

Reagent suppliers — provide mPEG-SCM derivatives and G-CSF-grade CHO cell banks for cGMP bioreactors

Biologic API manufacturers — execute PEGylation, tangential-flow filtration, and viral inactivation to yield bulk drug substance

Finished-dose contract packagers — integrate pre-filled syringes with needle guards and temperature indicators for oncology cold-chain

Regulatory consultants — compile comparability protocols enabling FDA 351(k) biosimilar or EMA hybrid pathway submissions

Distributors / hospital purchasing groups — negotiate multi-year tenders linking biosimilar uptake to reimbursement reference pricing

Oncology clinics — administer same-day or next-day post-chemotherapy injection, capturing bundled episode-of-care payments

Health technology assessors — generate cost-offset models comparing pegfilgrastim to daily filgrastim for febrile-neutropenia avoidance

Control resides with originator patents on PEG-protein linker stability; biosimilar entrants face 18- to 24-month regulatory review and interchangeability switching barriers. Supply risk centers on single-source specialty PEG reagents and FDA-inspected CHO capacity, requiring dual sourcing clauses. Value flows through tender bids where sole-supply status locks formularies for 12–36 months; exit costs include staff retraining and re-credentialing of electronic prescribing pathways. Value chain analysis shows EU markets accepting multi-biosimilar competition, while U.S. adoption hinges on payer step-therapy edits and White-Bagging mandates that shift procurement risk to specialty pharmacies.

Recent Industry Insights

The Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) industry trends have pivoted sharply toward biosimilar integration and digital-supply resilience in the past 18 months. Fresenius Kabi’s March-2024 launch of Stimufend® in the EU, supported by a closed-loop eco-injector, signaled a move to patient-administered, home-care formats, while Sandoz accelerated penetration by acquiring Klinge’s high-yield PEGylation platform (deal closed Jan-2024), securing cost-of-goods below €15 per dose. On the regulatory front, the FDA’s Sept-2023 guidance now allows interchangeability extrapolation from 6-month PK data—cutting development timelines by 10-12 months and prompting Coherus and Hangzhou Jiuyuan to file dual 351(k) + 351(a) hybrid applications for their once-per-cycle candidates. Private capital is chasing AI-driven glyco-optimization: AitiumBio closed a $42 m Series B (Apr-2024) to scale its G-CSF-Fc half-life extension algorithm, projecting 40% dose reduction. Meanwhile, hospital purchasers are shifting tenders to carbon-neutral vials, awarding Fresenius an 18% price premium in German group procurement rounds—an enterprise trend expected to ripple across Europe through 2025.

Analyst Overview

The Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market outlook remains structurally attractive, underpinned by rising chemotherapy cycles and a global shift toward once-per-cycle prophylaxis. Competitive intensity is moderate but rising: three biosimilar entrants in the U.S. and two in the EU have compressed originator share to 62 %, yet interchangeability barriers and payer tenders keep gross-to-net spreads healthy. Long-term, we forecast 6 % CAGR through 2032, supported by emerging-market volume catch-up and label expansion into severe chronic neutropenia. Innovation is pivoting to Fc-fusion and albumin-alternative half-life extension platforms that could halve injection frequency and unlock pediatrics; however, late-phase assets are at least four years away. Supply is stable—recombinant capacity utilization is 78 %—while demand is tracking 3 % ahead of forecast, keeping the market in balanced tension. Key risks include U.S. policy-driven ASP caps, China VBP roll-off compressing local prices >45 %, and potential J-code bundling that would commoditize administration. Portfolio hedging across biobetter candidates and ex-U.S. volume contracts is now table stakes.

11 items

1. Executive Summary

2. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital and Clinic

6.1.2. Pharmacy

6.1.3. Other

6.2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Pegfilgrastim

6.2.2. Lenograstim

6.2.3. Other

6.3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competition by Key Manufacturers

8.1. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Amgen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Mylan

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Kashiv BioSciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Pfizer

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Fresenius Kabi

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Coherus BioSciences

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Sandoz

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Italfarmaco SpA

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Evive Biotech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Chugai Pharmaceutical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Jiangsu Hengrui Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Amoytop Biotech

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Qilu Pharmaceutical

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. CSPC Baike Biopharma

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. SL Pharm

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Lunan Pharmaceutical

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market

Figure 4: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Drivers

Figure 5: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Challenges

Figure 6: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Trends

Figure 7: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Opportunity

Figure 8: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Restraint

Figure 9: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value (USD Million) By Region

Figure 15: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value (USD Million) By Region

Figure 23: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value (USD Million) By Region

Table 10: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Amgen Basic Information And Sales Area

Table 31: Amgen. Products Portfolio

Table 32: Mylan Basic Information And Sales Area

Table 33: Mylan. Products Portfolio

Table 34: Kashiv BioSciences Basic Information And Sales Area

Table 35: Kashiv BioSciences. Products Portfolio

Table 36: Pfizer Basic Information And Sales Area

Table 37: Pfizer. Products Portfolio

Table 38: Fresenius Kabi Basic Information And Sales Area

Table 39: Fresenius Kabi. Products Portfolio

Table 40: Coherus BioSciences Basic Information And Sales Area

Table 41: Coherus BioSciences. Products Portfolio

Table 42: Sandoz Basic Information And Sales Area

Table 43: Sandoz. Products Portfolio

Table 44: Italfarmaco SpA Basic Information And Sales Area

Table 45: Italfarmaco SpA. Products Portfolio

Table 46: Evive Biotech Basic Information And Sales Area

Table 47: Evive Biotech. Products Portfolio

Table 48: Chugai Pharmaceutical Basic Information And Sales Area

Table 49: Chugai Pharmaceutical. Products Portfolio

Table 50: Jiangsu Hengrui Pharmaceuticals Basic Information And Sales Area

Table 51: Jiangsu Hengrui Pharmaceuticals. Products Portfolio

Table 52: Amoytop Biotech Basic Information And Sales Area

Table 53: Amoytop Biotech. Products Portfolio

Table 54: Qilu Pharmaceutical Basic Information And Sales Area

Table 55: Qilu Pharmaceutical. Products Portfolio

Table 56: CSPC Baike Biopharma Basic Information And Sales Area

Table 57: CSPC Baike Biopharma. Products Portfolio

Table 58: SL Pharm Basic Information And Sales Area

Table 59: SL Pharm. Products Portfolio

Table 60: Lunan Pharmaceutical Basic Information And Sales Area

Table 61: Lunan Pharmaceutical. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value (USD Million) By Region

Table 67: Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the current Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size?

Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size surpassed USD 4.8 billion in 2023, driven by rising chemotherapy adoption and supportive biosimilar competition.

2. How fast will the market grow through 2030?

Analysts project a 6.2% CAGR, lifting the sector to USD 7.3 billion by 2030 as extended-duration G-CSF formulations gain frontline status worldwide.

3. What are the primary growth drivers?

Key catalysts include escalating cancer incidence, increasing prophylactic use in chemotherapy, cost-saving biosimilars, once-per-cycle dosing convenience, and favorable reimbursement across major markets.

4. Which challenges could restrain expansion?

Price erosion from biosimilars, stringent cold-chain logistics, risk of severe splenic adverse events, and variable reimbursement in emerging economies temper near-term revenue upside.

5. Which regions lead adoption today?

North America commands 48% share thanks to high treatment awareness, while Europe follows with biosimilar uptake; China and India are forecast to outpace mature markets post-2026.

6. Who are the top companies shaping competition?

Amgen’s Neulasta franchise still leads share, but biosimilar heavyweights including Pfizer, Mylan/Viatris, Coherus, and Sandoz are rapidly eroding price premiums through global launches.

7. What future opportunities exist for stakeholders?

Combinations with immuno-oncology agents, autoinjector devices, pediatric indications, and emerging markets penetration present the most attractive white-space opportunities for portfolio expansion.

8. How is technology impacting product development?

PEGylation advances, Fc-fusion half-life extension, smart wearable injectors, and AI-driven supply forecasting are reducing dosing frequency, improving adherence, and optimizing inventory costs.

9. How is the regulatory landscape evolving?

FDA and EMA now offer interchangeable biosimilar pathways, while China’s NMPA shortens review timelines; sponsors that meet comparability standards can secure rapid, price-competitive entry.

Contact for Full Report

Loading report content...

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Intelligence Report 2026 — Updated June 2026

Market Snapshot

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segmentation

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size?

2. How fast will the market grow through 2030?

3. What are the primary growth drivers?

4. Which challenges could restrain expansion?

5. Which regions lead adoption today?

6. Who are the top companies shaping competition?

7. What future opportunities exist for stakeholders?

8. How is technology impacting product development?

9. How is the regulatory landscape evolving?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segmentation

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size?

2. How fast will the market grow through 2030?

3. What are the primary growth drivers?

4. Which challenges could restrain expansion?

5. Which regions lead adoption today?

6. Who are the top companies shaping competition?

7. What future opportunities exist for stakeholders?

8. How is technology impacting product development?

9. How is the regulatory landscape evolving?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation